BiotechTube

RN624 + RN624 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic

Trial Timeline

Dec 19, 2007 → Jan 7, 2009

NCT ID
NCT00568321

About RN624 + RN624 + Placebo

RN624 + RN624 + Placebo is a phase 2 stage product being developed by Pfizer for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT00568321. Target conditions include Neuralgia, Postherpetic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00568321Phase 2Completed

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors
ProductCompanyStageHype Score
Placebo + DS-5565Daiichi SankyoPre-clinical
23
QUTENZAAstellas PharmaApproved
85
ASP8477 + PlaceboAstellas PharmaPhase 2
52
E2007 (perampanel) + PlaceboEisaiPhase 2
52
E2007EisaiPhase 2/3
65
KHK6188 + PlaceboKyowa KirinPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
GalcanezumabEli LillyApproved
85
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
ABT-894 + ABT-894 + ABT-894 + placebo + DuloxetineAbbViePhase 2
52
MK-8291 + PlaceboMerckPhase 1
33
Etoricoxib + PlaceboMerckApproved
85
Cetuximab + PlaceboMerckPhase 2
52
ADL5747 + Placebo + PregabalinMerckPhase 2
52
MK0759MerckPhase 2
52
MK0686MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
EMA401 + PlaceboNovartisPhase 2
52
pregabalinPfizerApproved
84
Lyrica (pregabalin) + PlaceboPfizerApproved
84

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84